HER2 Support Group Forums - View Single Post - Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Surviv

News · 10-31-2009, 04:11 AM

Eisai Inc. announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

More...

10-31-2009, 04:11 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,103	Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Surviv Eisai Inc. announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer. More...